Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders.
Cerevel Therapeutics has raised $450.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2023.
Cerevel Therapeutics's investors include RA Capital Management, Bain Capital, Pfizer, Adage Capital Management, Perceptive Advisors.
Cerevel Therapeutics is headquartered in Boston, United States.
Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders.
Cerevel Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cerevel Therapeutics — Funding & Investors." VCBacked, October 11, 2023, https://www.vcbacked.co/company/cerevel-therapeutics. Accessed November 12, 2026.
VCBacked. (2023). Cerevel Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/cerevel-therapeutics
{{cite web |title=Cerevel Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cerevel-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Cerevel Therapeutics? Request a listing update